Disease · MONDO_0005545
staphylococcus aureus infection
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. staphylococcus aureus infection. Diseases, record MONDO_0005545. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005545
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AMIKACIN SULFATE | CHEMBL4208954 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| AUROGRAB | CHEMBL2109569 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| CEFTOBIPROLE MEDOCARIL SODIUM | CHEMBL4297101 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DAPTOMYCIN | CHEMBL387675 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TELAVANCIN | CHEMBL507870 | Protein | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CEFAZOLIN | CHEMBL1435 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLOXACILLIN | CHEMBL222645 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MUPIROCIN | CHEMBL719 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TEFIBAZUMAB | CHEMBL2108055 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LTX-109 | CHEMBL1817968 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets0
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
None in this release.
Trials9
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03138733 | Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia | Phase 3 | 390 | 2023-05-06 | Staphylococcus Aureus Bacteremia | CEFTOBIPROLE MEDOCARIL SODIUM, DAPTOMYCIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01827358 | Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants | Phase 2 | 155 | 2017-07-07 | Staphylococcal Infection | MUPIROCIN | Its record names the disease | ClinicalTrials.gov |
| NCT01591785 | Treatment of Staphylococcus Aureus Colonization in Hand Eczema | Not applicable | 60 | 2020-12-03 | Hand Eczema, Foot Eczema | RETAPAMULIN | Its record names the disease | ClinicalTrials.gov |
| NCT01321879 | Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients | Phase 2 | 40 | 2019-12-27 | Infection, Bacteremia | TELAVANCIN | Its record names the disease | ClinicalTrials.gov |
| NCT00217841 | Aurograb and Vancomycin in MRSA Infection | Phase 3 | 180 | Staphylococcal Infections | AUROGRAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05655091 | Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection | Phase 2 | 36 | Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI) | CEFAZOLIN, FLOXACILLIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02753855 | Pharmacokinetics of Telavancin in Normal and Obese Subjects | Phase 1 | 32 | Healthy | TELAVANCIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00198289 | Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs | Phase 2 | 30 | Staphylococcus Aureus | TEFIBAZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01158235 | A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA) | Phase 1/2 | 24 | Nasal Carriers MRSA | LTX-109 | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ceftobiprole vs Daptomycin: deaths from any cause | 17 of 191 | 18 of 198 | 389 | NCT03138733 | Trial comparisons |
| Ceftobiprole vs Daptomycin: serious adverse events | 36 of 191 | 45 of 198 | 389 | NCT03138733 | Trial comparisons |
| Ceftobiprole vs Daptomycin: Number of Patients With Microbiological Eradication at the PTE Visit | 155 of 189 | 153 of 198 | 387 | NCT03138733 | Trial comparisons |
| Mupirocin (Treatment) vs No Mupirocin (Control): serious adverse events | 3 of 80 | 0 of 75 | 155 | NCT01827358 | Trial comparisons |
Mupirocin (Treatment) vs No Mupirocin (Control): Primary Decolonization Efficacy- Number of Participants in the Treatment and Control Groups Who Have no Detectable S. Aureus (SA) on Direct Nasal, Umbilical, and Perianal (NUP) Cultures Obtained on Day 8. | 62 of 66 | 3 of 64 | 130 | NCT01827358 | Trial comparisons |
Mupirocin (Treatment) vs No Mupirocin (Control): Persistent Decolonization Efficacy- Number of Participants in the Treatment and Control Groups Who Have no Detectable S. Aureus (SA) on Direct Nasal, Umbilical, and Perianal (NUP) Cultures on Days 8 and 22. | 21 of 46 | 1 of 48 | 94 | NCT01827358 | Trial comparisons |
| Retapamulin 1% Ointment vs Placebo Ointment: Number of Participants With PGA of 0 or 1 | 15 of 30 | 11 of 30 | 60 | NCT01591785 | Trial comparisons |
| Retapamulin 1% Ointment vs Placebo Ointment: deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT01591785 | Trial comparisons |
| Retapamulin 1% Ointment vs Placebo Ointment: Number of Participants With PGA of 0 or 1 | 22 of 30 | 14 of 30 | 60 | NCT01591785 | Trial comparisons |
| Retapamulin 1% Ointment vs Placebo Ointment: serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT01591785 | Trial comparisons |
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005545
GET https://conductscience.org/api/diseases/v1/MONDO_0005545/drugs